Bluebird Bio Inc. (NASDAQ:BLUE) released its earnings for the fourth-quarter of fiscal 2014 (4QFY14) on Wednesday, missing the consensus earnings estimate but beating the consensus revenue estimate. Adjusted loss per share for the quarter came in at $0.67, which fell short of the Streets estimate of $0.59. Quarterly revenues totaled $6.4 million, which exceeded the consensus estimate of $6.2 million.
Heres Why Piper Jaffray Hiked Price Objective On Bluebird Bio Inc (BLUE) To $119
Bidness etc. - 26 Feb 2015 23:38
Bluebird Bio Inc. (NASDAQ:BLUE) released its earnings for the fourth-quarter of fiscal 2014 (4QFY14) on Wednesday, missing the consensus earnings estimate but beating the consensus revenue estimate. Adjusted loss per share for the quarter came in at $0.67, which fell short of the Streets estimate of $0.59. Quarterly revenues totaled $6.4 million, which exceeded the consensus estimate of $6.2 million.
Share this Article
Recommended